Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 192594, 8 pages
http://dx.doi.org/10.1155/2014/192594
Research Article

Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis

Department of Public Health and Infectious Diseases, “ Sapienza” University of Rome, Viale del Policlinico 155, 00161 Rome, Italy

Received 26 June 2014; Revised 13 September 2014; Accepted 14 September 2014; Published 14 October 2014

Academic Editor: Fulvio D’Acquisto

Copyright © 2014 Alessandra D’Abramo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Jeong, H. W. Kim, N. S. Ku et al., “Clinical factors associated with carotid plaque and intima-medial thickness in HIV-infected patients,” Yonsei Medical Journal, vol. 54, no. 4, pp. 990–998, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Hakeem, S. Bhatti, and M. Cilingiroglu, “The spectrum of atherosclerotic coronary artery disease in HIV patients,” Current Atherosclerosis Reports, vol. 12, no. 2, pp. 119–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. G. D'Ettorre, M. Francone, M. Mancone et al., “Significant coronary stenosis detected by coronary computed angiography in asymptomatic HIV infected subjects,” Journal of Infection, vol. 64, no. 1, pp. 82–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. S. G. Deeks, “HIV infection, inflammation, immunosenescence, and aging,” Annual Review of Medicine, vol. 62, pp. 141–155, 2011. View at Publisher · View at Google Scholar
  5. J. M. Brenchley, T. W. Schacker, L. E. Ruff et al., “CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract,” Journal of Experimental Medicine, vol. 200, no. 6, pp. 749–759, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial translocation is a cause of systemic immune activation in chronic HIV infection,” Nature Medicine, vol. 12, no. 12, pp. 1365–1371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Le Saux, C. M. Weyand, and J. J. Goronzy, “Mechanisms of immunosenescence: lessons from models of accelerated immune aging,” Annals of the New York Academy of Sciences, vol. 1247, no. 1, pp. 69–82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Coll, S. Parra, C. Alonso-Villaverde et al., “The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection,” Stroke, vol. 38, no. 9, pp. 2477–2484, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Merlini, K. Luzi, E. Suardi et al., “T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis,” PLoS ONE, vol. 7, no. 9, Article ID e46073, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Guzmán-Fulgencio, J. Medrano, N. Rallón et al., “Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy,” Journal of Infection, vol. 63, no. 5, pp. 382–390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Biasillo, M. Leo, R. della Bona, and L. M. Biasucci, “Inflammatory biomarkers and coronary heart disease: from bench to bedside and back,” Internal and Emergency Medicine, vol. 5, no. 3, pp. 225–233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. W. Worm and P. Hsue, “Role of biomarkers in predicting CVD risk in the setting of HIV infection?” Current Opinion in HIV and AIDS, vol. 5, no. 6, pp. 467–472, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. A. D'Abramo, C. D'Agostino, A. Oliva et al., “Early atherosclerosis in HIV infected subjects on suppressive antiretroviral treatment: role of osteoprotegerin,” ISRN AIDS, vol. 2013, Article ID 737083, 6 pages, 2013. View at Publisher · View at Google Scholar
  14. L. C. Hofbauer and M. Schoppet, “Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases,” The Journal of the American Medical Association, vol. 292, no. 4, pp. 490–495, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Ssinabulya, J. Kayima, C. Longenecker et al., “Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda,” PLoS ONE, vol. 9, no. 2, Article ID e89537, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. J. Lee and S. Park, “The role of carotid ultrasound for cardiovascular risk stratification beyond traditional risk factors,” Yonsei Medical Journal, vol. 55, no. 3, pp. 551–557, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Kestens, G. Vanham, P. Gigase et al., “Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection,” AIDS, vol. 6, no. 8, pp. 793–797, 1992. View at Publisher · View at Google Scholar · View at Scopus
  18. R. B. Effros, “Loss of CD28 expression on T lymphocytes: a marker of replicative senescence,” Developmental and Comparative Immunology, vol. 21, no. 6, pp. 471–478, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Mancia, R. Fagard, K. Narkiewicz et al., “2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension,” Journal of Hypertension, vol. 31, no. 10, pp. 1925–1938, 2013. View at Publisher · View at Google Scholar
  20. J. S. Currier, “Update on cardiovascular complications in HIV infection,” Topics in HIV Medicine, vol. 17, no. 3, pp. 98–103, 2009. View at Google Scholar
  21. S. Ferrando-Martínez, E. Ruiz-Mateos, M. C. Romero-Sánchez et al., “HIV infection-related premature immunosenescence: high rates of immune exhaustion after short time of infection,” Current HIV Research, vol. 9, no. 5, pp. 289–294, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. L. E. Gamadia, E. M. M. van Leeuwen, E. B. M. Remmerswaal et al., “The size and phenotype of virus-specific T cell populations is determined by repetitive antigenic stimulation and environmental cytokines,” The Journal of Immunology, vol. 172, no. 10, pp. 6107–6114, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. F. T. Hakim and R. E. Gress, “Immunosenescence: immune deficits in the elderly and therapeutic strategies to enhance immune competence,” Expert Review of Clinical Immunology, vol. 1, no. 3, pp. 443–458, 2005. View at Google Scholar
  24. L. Papagno, C. A. Spina, A. Marchant et al., “Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection,” PLoS Biology, vol. 2, no. 2, article e20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Tassiopoulos, A. Landay, A. C. Collier et al., “CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies,” Journal of Infectious Diseases, vol. 205, no. 11, pp. 1730–1738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Grunfeld, J. A. Delaney, C. Wanke et al., “Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study,” AIDS, vol. 23, no. 14, pp. 1841–1849, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Lichtner, M. R. Cuomo, R. Rossi et al., “Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment,” Atherosclerosis, vol. 204, no. 2, pp. e1–e3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. W. Lorenz, C. Stephan, A. Harmjanz et al., “Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis,” Atherosclerosis, vol. 196, no. 2, pp. 720–726, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. O. Melander, C. Newton-Cheh, P. Almgren et al., “Novel and conventional biomarkers for prediction of incident cardiovascular events in the community,” The Journal of the American Medical Association, vol. 302, no. 1, pp. 49–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. A. C. Ross, N. Rizk, M. A. O'Riordan et al., “Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy,” Clinical Infectious Diseases, vol. 49, no. 7, pp. 1119–1127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Metkus Jr., T. T. Brown, and W. S. Post, “Cardiovascular disease associated with the human immunodeficiency virus: an update,” Current Treatment Options in Cardiovascular Medicine, vol. 16, no. 11, p. 346, 2014. View at Publisher · View at Google Scholar
  32. A. van Campenhout and J. Golledge, “Osteoprotegerin, vascular calcification and atherosclerosis,” Atherosclerosis, vol. 204, no. 2, pp. 321–329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J. J. Hwang, J. Wei, S. Abbara, S. K. Grinspoon, and J. Lo, “Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients,” Journal of Acquired Immune Deficiency Syndromes, vol. 61, no. 3, pp. 359–363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Kiechl, P. Werner, M. Knoflach, M. Furtner, J. Willeit, and G. Schett, “The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease,” Expert Review of Cardiovascular Therapy, vol. 4, no. 6, pp. 801–811, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. B. F. Boyce and L. Xing, “Functions of RANKL/RANK/OPG in bone modeling and remodeling,” Archives of Biochemistry and Biophysics, vol. 473, no. 2, pp. 139–146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Reid and I. Holen, “Pathophysiological roles of osteoprotegerin (OPG),” European Journal of Cell Biology, vol. 88, no. 1, pp. 1–17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Stejskal, J. Bartek, R. Pastorková, V. Růžička, I. Oral, and D. Horalík, “Osteoprotegerin, RANK, RANKL,” Biomedical Papers, vol. 145, no. 2, pp. 61–64, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. H. L. Wright, H. S. McCarthy, J. Middleton, and M. J. Marshall, “RANK, RANKL and osteoprotegerin in bone biology and disease,” Current Reviews in Musculoskeletal Medicine, vol. 2, no. 1, pp. 56–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Schoppet, A. M. Sattler, J. R. Schaefer, M. Herzum, B. Maisch, and L. Hofbauer, “Increased osteoprotegerin serum levels in men with coronary artery disease,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 3, pp. 1024–1028, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Vik, E. B. Mathiesen, J. Brox et al., “Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø study,” Journal of Thrombosis and Haemostasis, vol. 9, no. 4, pp. 638–644, 2011. View at Publisher · View at Google Scholar · View at Scopus